Literature DB >> 12359149

Inhibition of neuronal apoptosis in vitro and in vivo using TAT-mediated protein transduction.

Gunnar P H Dietz1, Ertugrul Kilic, Mathias Bähr.   

Abstract

The HIV TAT protein contains an 11-amino-acid protein transduction domain which acts as a "Trojan peptide": Linked to other macromolecules, it carries them across cellular membranes. Here, we demonstrate for the first time that fusion of the TAT protein transduction domain to an antiapoptotic protein represents a feasible technique to rescue neurons from apoptotic degeneration in vitro and in vivo. When fused to the antiapoptotic protein Bcl-X(L), it mediated uptake of the fusion protein into neurons. Once inside the cells, TAT-Bcl-X(L) was stable for many days and maintained its antiapoptotic function. It completely blocked low-potassium-induced apoptosis of cerebellar granule cells in vitro. In vivo, 24% of mouse retinal ganglion cells were prevented from undergoing retrograde neuronal apoptosis caused by optic nerve lesion when TAT-Bcl-X(L) was intraocularly injected. The application of TAT fusion proteins may in the future greatly facilitate neuroprotective therapy strategies for neurological disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12359149     DOI: 10.1006/mcne.2002.1165

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  22 in total

Review 1.  Cell penetrating peptides in drug delivery.

Authors:  Eric L Snyder; Steven F Dowdy
Journal:  Pharm Res       Date:  2004-03       Impact factor: 4.200

Review 2.  [Programmed cell death in the retina. Molecular mechanisms and therapeutic strategies].

Authors:  P Kermer; M Bähr
Journal:  Ophthalmologe       Date:  2005-07       Impact factor: 1.059

Review 3.  Inhibition of mitochondrial neural cell death pathways by protein transduction of Bcl-2 family proteins.

Authors:  Lucian Soane; Gary Fiskum
Journal:  J Bioenerg Biomembr       Date:  2005-06       Impact factor: 2.945

Review 4.  The taming of the cell penetrating domain of the HIV Tat: myths and realities.

Authors:  Ashok Chauhan; Akshay Tikoo; Arvinder K Kapur; Mahavir Singh
Journal:  J Control Release       Date:  2006-11-17       Impact factor: 9.776

5.  Characterisation of cell-penetrating peptide-mediated peptide delivery.

Authors:  Simon W Jones; Richard Christison; Ken Bundell; Catherine J Voyce; Sarah M V Brockbank; Peter Newham; Mark A Lindsay
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

6.  Anti-apoptotic therapy with a Tat fusion protein protects against excitotoxic insults in vitro and in vivo.

Authors:  Kevin L Ju; Nathan C Manley; Robert M Sapolsky
Journal:  Exp Neurol       Date:  2007-12-23       Impact factor: 5.330

7.  The C terminus of the nucleoprotein of influenza A virus delivers antigens transduced by Tat to the trans-golgi network and promotes an efficient presentation through HLA class I.

Authors:  Francesca Bettosini; Maria Teresa Fiorillo; Adriana Magnacca; Laura Leone; Maria Rosaria Torrisi; Rosa Sorrentino
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

8.  Inhibition of Epstein-Barr virus-induced growth proliferation by a nuclear antigen EBNA2-TAT peptide.

Authors:  Christopher J Farrell; Jae Myun Lee; Eui-Cheol Shin; Marek Cebrat; Philip A Cole; S Diane Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-19       Impact factor: 11.205

9.  Cell-penetrating peptides do not cross mitochondrial membranes even when conjugated to a lipophilic cation: evidence against direct passage through phospholipid bilayers.

Authors:  Meredith F Ross; Aleksandra Filipovska; Robin A J Smith; Michael J Gait; Michael P Murphy
Journal:  Biochem J       Date:  2004-11-01       Impact factor: 3.857

10.  Single-cell imaging of retinal ganglion cell apoptosis with a cell-penetrating, activatable peptide probe in an in vivo glaucoma model.

Authors:  Edward M Barnett; Xu Zhang; Dustin Maxwell; Qing Chang; David Piwnica-Worms
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.